Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    20154220 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia
Conditions: Acute Myelogenous Leukemia;   Myeloid Leukemia in Remission;   Effects of Immunotherapy
Intervention: Biological: Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)

Indicates status has not been verified in more than two years